Menu Search
Equities

CardieX Ltd

CDEXF:PKC

CardieX Ltd

Actions
  • Price (USD)0.04
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 17 2021.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CardieX Limited is an Australia-based digital health technology company. The Company develops and markets noninvasive patient monitoring technologies for assessing cardiovascular health. It specializes in the development of biomarkers and digital solutions for large-scale cardiovascular health disorders. Its solutions are designed to be deployed at point-of-care for arterial health screening, and as part of a remote patient monitoring regimen to extend care and enhance cardiovascular health outcomes. Its suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders all based on the Company’s SphygmoCor vascular biomarker technology. Its products include CONNEQT Pulse, SphygmoCor XCEL, and Oscar 2 Ambulatory Blood Pressure Monitor. CONNEQT Pulse measures both brachial and central blood pressures alongside a suite of vascular biomarkers to provide unparalleled insights into vascular health.

  • Revenue in AUD (TTM)11.18m
  • Net income in AUD-6.77m
  • Incorporated2005
  • Employees26.00
  • Location
    CardieX LtdSuite 301, 15 Lime St.SYDNEY NSW 2000AustraliaAUS
  • Phone+61 29874-8761
  • Websitehttps://cardiex.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.